Cite
HARVARD Citation
Li, L. et al. (2021). Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clinical and translational allergy. 11 (4), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Li, L. et al. (2021). Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clinical and translational allergy. 11 (4), p. n/a. [Online].